
Jazz Pharmaceuticals (NASDAQ:JAZZ) announced top-line results from the Phase 3 clinical trial investigating nabiximols oromucosal spray (JZP378) on clinical measures of spasticity in individuals with multiple sclerosis (MS).
The RELEASE MSS1 study evaluated the safety and efficacy of nabiximols oromucosal spray in 68 patients with multiple sclerosis (MS) spasticity, was the first and smallest, of the three clinical trials in the current program.